MedPath

Apomorphine

Generic Name
Apomorphine
Brand Names
Apokyn
Drug Type
Small Molecule
Chemical Formula
C17H17NO2
CAS Number
58-00-4
Unique Ingredient Identifier
N21FAR7B4S
Background

Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.

Apomorphine was granted FDA approval on 20 April 2004.

Indication

Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.

Associated Conditions
Mobility decreased
Clinical Trials
Related News

Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2009-08-10
Last Posted Date
2017-03-15
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
58
Registration Number
NCT00955318

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

Phase 2
Suspended
Conditions
Brain Injury
Interventions
Drug: Placebo
First Posted Date
2008-09-29
Last Posted Date
2017-03-31
Lead Sponsor
NeuroHealing Pharmaceuticals Inc.
Target Recruit Count
76
Registration Number
NCT00761228
Locations
🇺🇸

Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Phase 2
Withdrawn
Conditions
Parkinson's Disease
Interventions
First Posted Date
2008-09-25
Last Posted Date
2018-11-02
Lead Sponsor
Oregon Health and Science University
Registration Number
NCT00758368
Locations
🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy

Phase 2
Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2008-02-07
Last Posted Date
2020-08-28
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
16
Registration Number
NCT00610103

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study

Not Applicable
Completed
Conditions
Parkinson's Disease
Interventions
Drug: placebo
First Posted Date
2007-09-05
Last Posted Date
2008-04-11
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
16
Registration Number
NCT00524914
Locations
🇫🇷

Service de Neurologie, Toulouse, France

Low Dose Apomorphine and Parkinsonism

Phase 2
Withdrawn
Conditions
Parkinson's Disease
First Posted Date
2007-05-11
Last Posted Date
2018-11-29
Lead Sponsor
Oregon Health and Science University
Registration Number
NCT00472355
Locations
🇺🇸

Department of Neurology, Oregon Health and Science University, Mail Code OP32, 3181 SW Sam Jackson Park Road, Portland, Oregon, United States

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

Phase 2
Conditions
Alcoholism
First Posted Date
2007-02-19
Last Posted Date
2009-04-29
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
50
Registration Number
NCT00437177
Locations
🇪🇸

Psychiatry Service, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Phase 2
Completed
Conditions
Parkinson's Disease
First Posted Date
2006-06-30
Last Posted Date
2019-07-10
Lead Sponsor
Britannia Pharmaceuticals Ltd.
Target Recruit Count
36
Registration Number
NCT00346827

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Phase 3
Completed
Conditions
Parkinson Disease
First Posted Date
2005-09-20
Last Posted Date
2005-12-16
Lead Sponsor
Mylan Bertek Pharmaceuticals
Target Recruit Count
60
Registration Number
NCT00200525

Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

Phase 2
Completed
Conditions
Parkinson Disease
First Posted Date
2005-09-20
Last Posted Date
2005-12-16
Lead Sponsor
Mylan Bertek Pharmaceuticals
Target Recruit Count
16
Registration Number
NCT00200512
Locations
🇬🇧

The Morriston Hospital, Swansea, United Kingdom

🇬🇧

Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy